Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

INO-5401

Vaccine (DNA plasmid) · Immune activation, directed at Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (FOLH1) and human telomerase reverse transcriptase (TERT) · developed by INOVIO PHARMACEUTICALS

Phase 1/2 Most advanced trial

INO Developer

1 Registered trials

What is INO-5401?

INO-5401 is a DNA plasmid vaccine encoding three tumor-associated antigens: WT1, PSMA, and hTERT. Delivered intramuscularly with electroporation, it activates cytotoxic T-lymphocyte responses against cancer cells expressing these antigens. It is studied in glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (DNA plasmid)
Targets: Wilms tumor gene-1 (WT1) (antigen), prostate-specific membrane antigen (FOLH1) (antigen), human telomerase reverse transcriptase (TERT) (antigen)
Mechanism: Immune activation, directed at Wilms tumor gene-1 (WT1), prostate-specific membrane antigen (FOLH1) and human telomerase reverse transcriptase (TERT)
Pathways: cytotoxic T-lymphocyte response
Therapy area: Oncology
Developer: INOVIO PHARMACEUTICALS (INO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03491683	Phase 1/2	Glioblastoma	Active not recruiting	INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioblastoma

Other drugs acting on WT1 / FOLH1 / TERT

Gallium Ga 68 Gozetotide FDA approved ES414 Phase 1 Lutetium Lu 177 Rosopatamab Tetraxetan Phase 2

More from INOVIO PHARMACEUTICALS

DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Phase 1 INO-1400 Phase 1 INO-1401 Phase 1 INO-1800 Phase 1 INO-3106 Phase 1 INO-3107 Phase 1/2 INO-3401 Phase 1 INO-4201 Phase 1 INO-4202 Phase 1 INO-4212 Phase 1 INO-4500 Phase 1 INO-4700 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind INO-5401

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z